Ulcerative Colitis, Vitamin D Deficiency, Vitamin D Supplement
Conditions
Brief summary
It is uncertain whether vitD3 supplementation is beneficial for the remission of ulcerative colitis (UC). The effects of vitD3 supplements on the efficacy of vidrecizumab in Chinese UC patients were retrospectively analyzed. Methods: Patients with moderate to severe UC were recorded. These patients were initially treated with VDZ. VitD3 supplementation was defined as 400IU/d vitD3 supplementation during the first infusion of VDZ and continued throughout the follow-up period. Disease activity was assessed using the modified Mayo score.
Interventions
None listed
Sponsors
Second Affiliated Hospital of Wenzhou Medical University
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
15 Years to 65 Years
Inclusion criteria
* moderate-to-severe UC * Treated with Vedolizumab
Exclusion criteria
* had recent supplementation of vitD3 * pregnant * had cognitive/developmental disorders that affected their ability to complete the study procedures * had medical illness or therapies potentially affecting bone, nutrition or growth status * unknown or untested baseline serum 25(OH)D level
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Serum 25 (OH) D level | 30 weeks | Because serum 25 (OH) D levels are relatively stable, they are considered the most reliable indicator of vitamin D status. |
| disease activity | 30 weeks | modified Mayo score，mild: 3 to 5, moderate: 6 to 10, severe: 11 to 12 |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| drug survival | 54 week | Proportion of UC patients who continued to receive VDZ |
Countries
China
Outcome results
None listed